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E D I T O R I A L
Advances in measuring influenza burden of disease
1  | IMPORTANCE OF BURDEN OF 
DISEASE ESTIMATES
Influenza is a global public health threat, with seasonal and pandemic 
influenza resulting in substantial impact on health, the economy and 
society. The World Health Organization (WHO) has recently estimated 
that every year, 290 000 to 650 000 deaths are associated with re-
spiratory diseases from seasonal influenza.1 This estimate takes into 
account findings from recent influenza respiratory mortality studies, 
including a study conducted by Iuliano et al.2 Many high- income coun-
tries (HICs) that have invested in measuring the impact of influenza 
epidemics and the cost- effectiveness of interventions against influ-
enza have also spent substantial resources in preventing spread and 
mitigating health outcomes through vaccination, clinical management 
of severe cases and other public health measures. At the same time, 
many low- and middle- income countries (LMICs), especially those in 
the tropics, are grappling with understanding the impact of influenza 
in their local setting, and to determine whether such interventions are 
cost- effective vis- à- vis interventions for other diseases.3 Furthermore, 
LMICs are likely to have the highest burden of influenza in children, 
but these are also the countries with the least data available.4
2  | EFFORTS TO EXPAND BURDEN OF 
DISEASE STUDIES
It is in this context that burden of disease studies are important to doc-
ument the potential impact of influenza on various aspects of health. 
This includes the number of cases among higher- risk populations, hos-
pitalizations and deaths. Estimates of national disease burden during 
influenza seasons will raise awareness on the impact of seasonal influ-
enza in the local setting. It will allow for cost- effectiveness analyses to 
aid decision- making on investments such as vaccination programmes, 
and can lead to an expansion of efforts to tackle the spread of influenza 
in regions where impact is highest. In countries that have conducted 
burden of disease and cost- effectiveness studies, influenza vaccina-
tion programmes have likewise taken root.5-8 Undertaking burden of 
disease studies for seasonal influenza also helps countries to develop 
surveillance and analytical capabilities for use during pandemics.
Previous influenza burden studies were performed mostly in HICs, 
whose results are not necessarily generalizable to LMICs because of 
differences in underlying determinants such as age structure, nutrition, 
prevalence of high- risk conditions, uptake of preventive strategies and 
access to medical care. Influenza- related research has been expand-
ing in LMICs over the last few years, showing that influenza causes 
substantial clinical cases, hospitalizations and deaths across various 
geographical and social settings.9-13 Research has also shown that 
the outcomes from influenza infection may be more severe in LMICs 
compared to HICs,14,15 and that LMICs contribute a disproportionate 
burden towards global influenza disease.4
However, influenza disease burden information is still sparse in 
regions such as Africa, Asia and South America where there are dif-
ferences in way that healthcare services are organized, accessed and 
financed across countries, even within the same region. There is also a 
relative lack of data from the tropics, where influenza exhibits different 
seasonal patterns compared to temperate countries.16 In addition to 
national considerations, determining more accurate regional and global 
burden of disease estimates for influenza is necessary to provide per-
spective on the impact caused by influenza compared to other diseases, 
and to determine investments to develop better pharmaceuticals such 
as vaccines with broad immunogenicity and improved vaccine produc-
tion methods. As the WHO global estimates are extrapolations from 
available national data, building accurate global estimates requires bet-
ter data from representative areas from all regions of the world.
Since 2015, the WHO has been encouraging countries who have yet 
to embark on burden of disease studies to do so by publishing A Manual 
for Estimating Disease Burden Associated with Seasonal Influenza under the 
ambit of the Pandemic Influenza Preparedness (PIP) framework.17 It has 
also supported the conduct of such studies in LMICs in regions where 
little data existed through funding and provision of technical expertise.
This Special Edition of the Journal showcases the output of this 
ongoing work, which has led to a new series of seasonal influenza bur-
den of disease studies.
3  | NEW SERIES OF BURDEN STUDIES
Eighteen population- specific articles have been included in this Special 
Edition—including five from Asia,18-22 four from Africa,23-26 four from 
Europe,27-30 three from North America,31-33 and one each from South 
America34 and the Middle East.35 (Figure 1 and Table 1) This reflects a 
broad geographical breadth of new research, and these data will add 
to our understanding of the burden of disease worldwide, especially 
in LMICs.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
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The heterogeneity of study designs is apparent and expected. 
Eight studies used the WHO manual in developing their methodol-
ogy,18,19,22,24,26,28,29,34 although this ranged from hospital admission 
surveys to adapting suggested analytic methods. Most studies brought 
together information from various sources, including primary data 
from sentinel sites, provincial or national databases, and virological 
surveillance networks. Statistical models used range from regression 
analyses to semi- parametric generalized additive models. The diver-
sity of methods shows that there are different ways in which countries 
can develop burden estimates, depending on the resources available.
Two studies in this Special Edition, from India and South Africa, 
evaluated various data sources and methods and determined the best 
approaches for developing disease burden estimates in their country. 
The study from India found that while the Sample Registration System 
provided the most appropriate national mortality data set, other 
mortality data sources could be used for subregional estimates.36 
The South African study showed that weekly proportion and influ-
enza subtype- specific proxies provided the best model fit with non- 
significant differences in the estimates.25
The outcomes also varied across studies. The most common 
outcomes were deaths attributable to influenza, used in nine stud-
ies,18,20,21,25,29,32,34,36 and severe acute respiratory infections (SARI) 
or its equivalent, used in eight studies.19,22,24,26,28,29,34 Another seven 
studies measured excess or absolute hospitalizations due to influ-
enza,27-29,31,32,34,35 and five studies measured community or outpatient 
visits.28-30,32,33 Some studies were less representative for the entire 
country than others—there were 10 studies that collected data from 
across the country, although most national estimates were calculated 
with the help of extrapolations and appropriate adjustments for demo-
graphic differences.18,24,27,29,31,33
Among the wealth of information in this supplement, five coun-
tries measure their influenza burden for the first time—Cambodia, 
Chile, Romania, Rwanda and Zambia.19,24,26,28,34 Fresh perspectives on 
influenza burden are also offered by the other studies. For example, 
studies from the United States and the United Kingdom shed light on 
the burden of disease in the community, including its effect on quality- 
adjusted life days and years.30,32,33
This Special Edition also includes a review of the risk factors for 
severe outcomes associated with influenza illness in HICs versus 
LMICs, showing differences in determinants for severe outcomes be-
tween the two settings. Pregnancy, living with HIV or AIDS and young 
age were found to be additional risk factors in LMICs but not in HICs. 
Furthermore, children with neurological conditions in LMIC also had a 
higher risk of severe outcomes than those from HICs.37
Lastly, to assist countries in translating their burden of disease 
data into economic and policy decisions on the use of vaccines, WHO 
has also developed an economic evaluation tool. This is described in a 
paper in this Special Edition, which summarizes the key components of 
the tool and its implications for public health.38
4  | THE WAY FORWARD
The diversity in methods used across various burden of disease studies 
is reflective of the multifaceted and complex nature of these estima-
tions. Certain methods may be easier to implement in some contexts 
F IGURE  1 Locations of population- specific articles in this Special Edition of the journal
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than others. For example, compared to hospitalizations, collecting 
accurate community- based data on influenza may be challenging in 
dispersed populations or less- resourced health systems. The different 
perspectives from the two studies in China also remind us that disease 
burden may vary within large countries with diverse populations.20,21
Likewise, there may be various factors behind whether countries 
use the approach described in the WHO manual for their estimations. 
Some methods and measures used in countries may have pre- dated 
the availability of the WHO manual or deemed to be a better fit for 
the country’s needs. Furthermore, extrapolation and modelling may be 
helpful where primary data are not readily available, and there are dif-
ferent ways in which countries may choose to do so. The WHO manual 
therefore serves as a useful reference for those conducting burden of 
disease studies for the first time, and for others looking to improve 
their future estimates.
Accurate burden of disease estimates is still dependent on the 
quality of primary data, and this is best obtained through robust 
local surveillance systems. As they also support early detection and 
response to emerging threats, strengthening national surveillance ca-
pabilities is in the interest of global health security and in line with 
capability building under the International Health Regulations.39 In this 
regard, there is room for additional support to be provided to countries 
encountering difficulties in setting up surveillance systems and burden 
of disease estimates, either in the form of financial or professional ex-
pertise. The increasing number of studies in less studied regions allows 
for some extrapolation to neighbouring countries, but there are limita-
tions. Extrapolation may be unavoidable for complex parameters, but 
each country and subregion is different and surveillance data are still 
required to provide a meaningful baseline.
Knowing the national and global burden of disease of seasonal 
influenza is an important first step in providing clarity on the mag-
nitude of the problem at hand. However, its true utility is when such 
information is used to guide public health actions. There is a need for 
guidance to support countries to translate these data into policies and 
practices that would help to reduce this burden. The WHO economic 
evaluation tool described above is one such example.38 By knowing 
the cost- effectiveness of different possible interventions, countries 
would have greater clarity on which measures should be prioritized, 
implemented and monitored.
Burden of disease studies are likely to continue to gain increased 
attention, especially with the increased emphasis on value- based 
health care and cost- effective decision- making. Each study represents 
a piece to a larger puzzle, and the collective wealth of country expe-
riences contribute to our better understanding of the overall global 
burden of disease of seasonal influenza, enable capacities to be built 
that can be used during a pandemic, and help inform us of how best 
to safeguard public health as individual nations and as part of a global 
community.
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